GHRP-2 Dosage, Protocol, and Reconstitution Guide
GHRP-2
GHRP-2 is a synthetic growth hormone secretagogue that binds to the ghrelin receptor and stimulates pulsatile GH release. It is commonly discussed for growth hormone support, recovery, fat metabolism, and body composition, but it is generally considered less selective than Ipamorelin.
How It Works
Ghrelin Receptor Activation → GH Pulse ↑ → IGF-1 ↑ → Recovery + Fat Loss + Appetite ↑
GHRP-2 activates the growth hormone secretagogue receptor (GHSR-1a), stimulating GH release from the pituitary. Human studies have demonstrated a strong GH response following GHRP-2 administration, while also showing that its endocrine activity is not completely selective for GH.
GHRP-2 is a growth hormone secretagogue that acts through the ghrelin receptor (GHSR-1a).
Human studies have demonstrated strong GH release following GHRP-2 administration.
Human research also shows that GHRP-2 can influence ACTH, cortisol, and prolactin, indicating that its endocrine activity is not completely GH-selective.
Published human research has primarily used intravenous administration, which should be distinguished from subcutaneous protocols commonly discussed in peptide communities.
GHRP-2 Research Protocol
5 mg vial + 3.0 mL BAC Water → 1 unit = 16.7 mcg → GH Pulse Support
Standard Setup
Vial
5 mg
Water
3.0 mL bacteriostatic water
Concentration
1.67 mg/mL
Conversion
1 unit = 16.7 mcg
Weeks 1–2
Start Phase
Dose100 mcg
Units6 units
Volume0.06 mL
Weeks 3–4
Build Phase
Dose150 mcg
Units9 units
Volume0.09 mL
Weeks 5–8
Peak Phase
Dose200 mcg
Units12 units
Volume0.12 mL
Weeks 9–12
Maintain Phase
Dose250 mcg
Units15 units
Volume0.15 mL
Protocol Details
FrequencyOnce daily
Timing30–60 min before bed, often fasted
Cycle Length8–12 weeks
Optional Longer UseUp to 16 weeks with planned break
Research / Community FrameworkNo standardized research cycle has been established
Important Context
Community SC protocols differ from published human study designs
Research context
Human studies demonstrate that GHRP-2 can strongly stimulate GH release, but commonly discussed subcutaneous microgram schedules should not be confused with established clinical dosing protocols.
Human studies demonstrate that GHRP-2 can strongly stimulate GH release, but commonly discussed subcutaneous microgram schedules should not be confused with established clinical dosing protocols.
Advanced Research Protocol
Higher Range
Advanced
Dose200–300 mcg daily
More Frequent Dosing
Multiple-daily or split-dose schedules are discussed in peptide and research communities.
An optimal subcutaneous dosing frequency has not been established through clinical trials.
Published IV research should not be interpreted as validation of community AM + PM dosing schedules.
Advanced Use:
Some protocols split dosing into AM + PM pulses, but once-daily bedtime use is the cleaner starting point for most structured protocols.
Some protocols split dosing into AM + PM pulses, but once-daily bedtime use is the cleaner starting point for most structured protocols.
How to Use GHRP-2 (Timing & Injection)
Use StyleGH pulse + recovery support
Timing30–60 min before bed
Food TimingDiscussed fasted for cleaner GH signaling
RouteSubcutaneous
Injection Notes
Subcutaneous injection
Common sites: abdomen, thigh, or upper arm
Often used fasted for cleaner GH signaling
Rotate injection sites consistently
Timing Notes
Bedtime timing is commonly discussed used for nighttime GH pulse support.
Fasted timing is often discussed because food may blunt GH signaling.
Some advanced protocols split AM + PM dosing, but this increases complexity.
Consistency matters more than pushing dose higher too quickly.
Reconstitution & Dosing (5 mg Vial)
Vial5 mg
Water3.0 mL
Concentration1.67 mg/mL
Conversion1 unit = 16.7 mcg
Dose Reference
6 units ≈ 100 mcg
9 units ≈ 150 mcg
12 units ≈ 200 mcg
15 units ≈ 250 mcg
18 units ≈ 300 mcg
Reconstitution Steps
Draw 3.0 mL bacteriostatic water
Inject slowly down vial wall
Gently swirl, do not shake
Allow powder to fully dissolve
Label with the reconstitution date
Refrigerate immediately after mixing
Storage & Shelf Life
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C
Long-term storage: freezing at −20°C is commonly preferred
Keep the vial sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Avoid leaving lyophilized peptide at room temperature for extended periods
Do not repeatedly freeze and thaw the same vial
Store upright when possible and keep away from condensation
Estimated Unmixed Shelf Life
Refrigerated (2–8°C): commonly ~12–24 months when sealed and dry
Frozen (−20°C): commonly up to ~2–3 years when stored properly
Actual stability depends on supplier quality, handling, and storage conditions
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C
Use within ~4 weeks
Do not freeze after mixing
Discard if cloudy, discolored, or if particles appear
Best Practice
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Lyophilized peptides are most stable when they stay cold, dry, sealed, and protected from light. Once mixed, the clock starts: keep refrigerated, avoid contamination, and use within the stated window.
Research Cycle Length & Time Between Cycles
GH Pulse Phase → Recovery / Body Composition Phase → Break → Reassess
Standard Research Cycle Structure
Cycle Length8–12 weeks
Optional Longer CycleUp to 16 weeks with planned break
Primary PhaseDaily GH pulse support
GoalRecovery + fat metabolism + body composition support
Established Cycle Length
No standardized cycle established
Time Between Cycles
Break4–8 weeks
Established Off-Cycle
No evidence-based off-cycle duration has been established
Reassessment can help evaluate GH / IGF-1 response and tolerability.
Appetite, glucose-related markers, fluid retention, and endocrine effects may also be relevant depending on the research context.
Why cycle?
GHRP-2 is short-acting and works through ghrelin receptor activation. Cycling is discussed to help maintain responsiveness, reduces the risk of diminishing returns, and gives a clear checkpoint to evaluate whether the protocol is helping.
GHRP-2 is short-acting and works through ghrelin receptor activation. Cycling is discussed to help maintain responsiveness, reduces the risk of diminishing returns, and gives a clear checkpoint to evaluate whether the protocol is helping.
When to Stop or Pause Early
Appetite becomes difficult to manage
Water retention becomes uncomfortable
Sleep quality worsens
Recovery benefits plateau or fade
You are continuing without a clear recovery, fat-loss, or body-composition goal
Important distinction
Published human research establishes that GHRP-2 can stimulate GH release, but it does not establish the 8–12 week cycles or 4–8 week breaks commonly discussed in peptide communities.
Published human research establishes that GHRP-2 can stimulate GH release, but it does not establish the 8–12 week cycles or 4–8 week breaks commonly discussed in peptide communities.
Human Clinical Research
Healthy Adult GH Response
Population
Healthy adult men
Administration
Intravenous GHRP-2
Finding
Strong GH response demonstrated
GH Peak
Observed approximately 20–45 minutes after administration
GHRH + GHRP-2 Research
Human studies have compared GHRP-2 with growth hormone-releasing hormone (GHRH).
In healthy volunteers, GHRP-2 produced a greater GH response than GHRH alone under the study conditions.
Combining GHRP-2 with GHRH produced an even larger GH response, supporting complementary signaling between the two pathways.
Endocrine Selectivity
GHRP-2 is not completely selective for growth hormone signaling.
Human research has documented increases in prolactin, ACTH, and cortisol following administration.
This endocrine activity is an important distinction when comparing GHRP-2 with more selective growth hormone secretagogues.
Critical Illness Research
GHRP-2 has also been studied in critically ill adults with altered GH / IGF-1 signaling.
Continuous GHRP-2 infusion substantially increased GH secretion and produced a significant increase in circulating IGF-1 within 24 hours in one clinical study.
These findings came from hospitalized critically ill patients and should not be interpreted as evidence for recreational body-composition, recovery, or anti-aging protocols.
Important research distinction:
Human research confirms that GHRP-2 can strongly stimulate GH release and influence the GH / IGF-1 axis. However, much of the published human research used intravenous administration and specialized clinical populations. Common subcutaneous microgram protocols used outside clinical research have not been validated through comparable clinical trials for fat loss, muscle growth, recovery, or anti-aging outcomes.
Human research confirms that GHRP-2 can strongly stimulate GH release and influence the GH / IGF-1 axis. However, much of the published human research used intravenous administration and specialized clinical populations. Common subcutaneous microgram protocols used outside clinical research have not been validated through comparable clinical trials for fat loss, muscle growth, recovery, or anti-aging outcomes.
Monitoring During Use
Sleep quality
Recovery and soreness
Body composition changes
Appetite response
IGF-1 levels on longer cycles
Water retention or hormone-related changes
Benefits
Demonstrated strong GH-releasing activity in human research
Can increase circulating IGF-1 under studied clinical conditions
GH / IGF-1 signaling is involved in metabolism, tissue maintenance, and body-composition pathways
Human research demonstrates complementary GH signaling when GHRP-2 is combined experimentally with GHRH
Potential Side Effects
Human studies have documented ACTH and cortisol increases under some experimental conditions
Prolactin increases have also been observed in human research
Glucose regulation and insulin requirements may be relevant safety considerations
FDA safety context:
FDA has identified potential safety concerns with compounded GHRP-2, including immunogenicity and peptide-related impurity concerns. Serious adverse events have also been reported in clinical settings, although FDA notes that causality has not been established for those reports.
FDA has identified potential safety concerns with compounded GHRP-2, including immunogenicity and peptide-related impurity concerns. Serious adverse events have also been reported in clinical settings, although FDA notes that causality has not been established for those reports.
Stacking Strategies
GH Pulse Support → Recovery + Metabolic Layering → Avoid Overlap Without a Plan
Combination Research
GHRH + GHRP-2: Human studies have demonstrated a greater GH response when GHRP-2 and GHRH were administered together than with either pathway alone under the studied conditions.
CJC-1295 NO DAC + GHRP-2: Commonly discussed as a modern GHRH + GHRP combination, but the specific community protocol should not be treated as equivalent to the combinations evaluated in published clinical studies.
BPC-157 + GHRP-2: Discussed in peptide communities for recovery, but direct human combination evidence is lacking.
What to Avoid
Stacking multiple GHRPs without a clear reason
Combining multiple GH secretagogues without understanding pathway overlap
Running long continuous cycles without planned breaks
Ignoring water retention, sleep, appetite, or hormone-related side effects
Simple rule
GHRP-2 can be useful when stronger GH pulse support is desired, but it is less selective than Ipamorelin. Stack carefully and avoid duplicating the same ghrelin-receptor signal unnecessarily.
GHRP-2 can be useful when stronger GH pulse support is desired, but it is less selective than Ipamorelin. Stack carefully and avoid duplicating the same ghrelin-receptor signal unnecessarily.
Important Notes
Less selective than Ipamorelin
More likely to increase appetite
Short-acting pulse makes timing matter
Works best with good sleep, training, and nutrition
Fasted timing is often preferred for cleaner GH signaling
Best used with planned cycling and monitoring
Important Disclaimer
GHRP-2 is not FDA-approved for therapeutic use in the United States. Human studies have investigated its effects on growth hormone and other endocrine pathways, but commonly discussed peptide-community protocols are not established FDA-approved treatment regimens. This content is provided for educational and research purposes only.
Research & References
Primary Research
- Arvat E, Di Vito L, Maccagno B, et al. Effects of GHRP-2 and Hexarelin, Two Synthetic GH-Releasing Peptides, on GH, Prolactin, ACTH and Cortisol Levels in Man. Peptides. 1997.
- Laferrère B, Abraham C, Russell CD, Bowers CY. Growth Hormone Releasing Peptide-2 (GHRP-2), Like Ghrelin, Increases Food Intake in Healthy Men. Journal of Clinical Endocrinology & Metabolism. 2005.
- Arvat E, Broglio F, Aimaretti G, et al. Ghrelin and Synthetic GH Secretagogues. Best Practice & Research Clinical Endocrinology & Metabolism. 2002.
Research Note: GHRP-2 (Pralmorelin) is well studied in human clinical research for its ability to stimulate pulsatile growth hormone release, but this evidence base comes from clinical/research-dose IV and subcutaneous studies—not from the specific self-administration protocols circulating in fitness and longevity communities. GHRP-2 also reliably raises cortisol, prolactin, and appetite more than newer secretagogues, so dosing decisions should account for that broader hormonal effect, not just GH output.
Comments
Post a Comment